LABT

Lakewood-Amedex Biotherapeutics, Inc.

Price Chart

Latest Quote

$2.56

+0.01 (+0.39%)

Current Price

Previous Close	$2.55
Open	$2.36
Day High	$2.85
Day Low	$2.15
Volume	893,896

Fetched: 2026-07-15T14:45:09

Stock Information

Shares Outstanding	1.75M
Total Debt	$1.76M
Cash Equivalents	$12K
Net Income	$-6.23M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$4.48M
EPS (TTM)	$-3.26
Exchange	NCM

🌐 Visit Website

Recent Price History

Date	Close	Volume
2026-07-17	$1.89	86,395
2026-07-16	$1.85	194,900
2026-07-15	$2.43	983,100
2026-07-14	$2.55	81,900
2026-07-13	$2.73	241,200
2026-07-10	$2.61	214,100
2026-07-09	$2.64	286,100
2026-07-08	$2.38	107,300
2026-07-07	$2.39	228,000
2026-07-06	$2.74	684,600
2026-07-02	$2.75	774,600
2026-07-01	$3.30	308,500
2026-06-30	$3.14	303,800
2026-06-29	$3.48	290,400
2026-06-26	$3.51	406,500
2026-06-25	$3.43	668,800
2026-06-24	$3.72	530,900
2026-06-23	$3.97	383,800
2026-06-22	$3.65	154,000
2026-06-18	$3.90	183,080

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

📰 Latest News

No news articles available at the moment. Check back later for updates on LABT.

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31
Revenue
Total Revenue	$0	$0	$0
Operating Revenue	$0	$0	$0
Expenses
Interest Expense	$100,881	$5,000	$10,000
Total Expenses	$3,772,370	$4,026,820	$8,636,719
Net Non Operating Interest Income Expense	$-75,267	$137,596	$350,122
Interest Expense Non Operating	$100,881	$5,000	$10,000
Operating Expense	$3,772,370	$4,026,820	$8,636,719
General And Administrative Expense	$2,512,470	$1,917,154	$3,096,208
Other Income Expense	-	$-966,181	$4,637
Other Non Operating Income Expenses	-	$77,000	$4,637
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-3,847,637	$-4,855,405	$-8,281,960
Net Interest Income	$-75,267	$137,596	$350,122
Interest Income	$25,614	$142,596	$360,122
Normalized Income	$-3,847,637	$-3,812,224	$-8,281,960
Net Income From Continuing And Discontinued Operation	$-3,847,637	$-4,855,405	$-8,281,960
Total Operating Income As Reported	$-3,772,370	$-4,026,820	$-8,636,719
Net Income Common Stockholders	$-3,847,637	$-4,855,405	$-8,281,960
Net Income	$-3,847,637	$-4,855,405	$-8,281,960
Net Income Including Noncontrolling Interests	$-3,847,637	$-4,855,405	$-8,281,960
Net Income Continuous Operations	$-3,847,637	$-4,855,405	$-8,281,960
Pretax Income	$-3,847,637	$-4,855,405	$-8,281,960
Special Income Charges	$0	$-1,042,459	$0
Interest Income Non Operating	$25,614	$142,596	$360,122
Operating Income	$-3,772,370	$-4,026,820	$-8,636,719
Depreciation Amortization Depletion Income Statement	$4,634	$6,300	$11,563
Depreciation And Amortization In Income Statement	$4,634	$6,300	$11,563
Depreciation Income Statement	$4,634	$6,300	$11,563
Per Share
Diluted EPS	$-2.76	$-6.94	$-11.84
Basic EPS	$-2.76	$-6.94	$-11.84
Other
Tax Effect Of Unusual Items	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-3,626,780	$-3,688,630	$-8,150,975
Total Unusual Items	$0	$-1,043,181	$0
Total Unusual Items Excluding Goodwill	$0	$-1,043,181	$0
Reconciled Depreciation	$119,976	$118,594	$120,985
EBITDA (Bullshit earnings)	$-3,626,780	$-4,731,811	$-8,150,975
EBIT	$-3,746,756	$-4,850,405	$-8,271,960
Diluted Average Shares	$1,393,564	$699,546	$699,546
Basic Average Shares	$1,393,564	$699,546	$699,546
Diluted NI Availto Com Stockholders	$-3,847,637	$-4,855,405	$-8,281,960
Research And Development	$1,255,266	$2,103,366	$5,528,948
Selling General And Administration	$2,512,470	$1,917,154	$3,096,208
Other Gand A	$1,428,141	$1,406,758	$1,166,453
Salaries And Wages	$1,084,329	$510,396	$1,851,084
Other Special Charges	-	$1,042,459	-
Gain On Sale Of Security	-	$-722	-
Insurance And Claims	-	$77,908	$78,671

Fetched: 2026-07-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31
Assets
Net Tangible Assets	$-1,964,537	$409,611	$4,558,327
Total Assets	$481,598	$1,070,581	$6,893,904
Total Non Current Assets	$176,209	$296,600	$413,348
Other Non Current Assets	$8,132	$8,547	$8,547
Current Assets	$305,389	$773,981	$6,480,556
Other Current Assets	$68,989	$92,883	$90,089
Cash Cash Equivalents And Short Term Investments	$236,400	$681,098	$6,390,467
Cash And Cash Equivalents	$236,400	$681,098	$2,529,756
Debt
Net Debt	$1,263,600	-	-
Total Debt	$1,660,341	$272,862	$578,884
Long Term Debt And Capital Lease Obligation	$41,035	$160,342	$272,862
Current Debt And Capital Lease Obligation	$1,619,306	$112,520	$306,022
Current Debt	$1,500,000	-	$200,000
Liabilities
Total Liabilities Net Minority Interest	$2,446,135	$660,970	$2,335,577
Total Non Current Liabilities Net Minority Interest	$41,035	$160,342	$272,862
Current Liabilities	$2,405,100	$500,628	$2,062,715
Current Notes Payable	$1,500,000	$0	$200,000
Payables And Accrued Expenses	$785,794	$388,108	$1,756,693
Interest Payable	$100,881	$0	$138,020
Payables	$381,041	$166,467	$499,066
Accounts Payable	$381,041	$166,467	$499,066
Equity
Common Stock Equity	$-1,967,577	$406,571	$4,555,287
Preferred Stock Equity	$3,040	$3,040	$3,040
Total Equity Gross Minority Interest	$-1,964,537	$409,611	$4,558,327
Stockholders Equity	$-1,964,537	$409,611	$4,558,327
Retained Earnings	$-53,351,130	$-49,503,493	$-44,648,088
Other
Treasury Shares Number	$4,786	-	-
Ordinary Shares Number	$1,393,564	$1,393,564	$1,393,564
Share Issued	$1,398,350	$1,393,564	$1,393,564
Tangible Book Value	$-1,967,577	$406,571	$4,555,287
Invested Capital	$-467,577	$406,571	$4,755,287
Working Capital	$-2,099,711	$273,353	$4,417,841
Capital Lease Obligations	$160,341	$272,862	$378,884
Total Capitalization	$-1,964,537	$409,611	$4,558,327
Treasury Stock	$150,000	$150,000	$100,000
Additional Paid In Capital	$51,532,849	$50,059,365	$49,302,689
Capital Stock	$3,744	$3,739	$3,726
Common Stock	$704	$699	$686
Preferred Stock	$3,040	$3,040	$3,040
Long Term Capital Lease Obligation	$41,035	$160,342	$272,862
Current Capital Lease Obligation	$119,306	$112,520	$106,022
Current Accrued Expenses	$404,753	$221,641	$1,257,627
Net PPE	$168,077	$288,053	$404,801
Accumulated Depreciation	$-68,179	$-63,545	$-57,245
Gross PPE	$236,256	$351,598	$462,046
Other Properties	$164,389	$279,731	$392,025
Machinery Furniture Equipment	$71,867	$71,867	$70,021
Other Short Term Investments	-	$0	$3,860,711

Fetched: 2026-07-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31
Free Cash Flow
Free Cash Flow	$-1,944,698	$-5,725,168	$-6,816,114
Operating Activities
Operating Cash Flow	$-1,944,698	$-5,723,322	$-6,816,114
Cash Flow From Continuing Operating Activities	$-1,944,698	$-5,723,322	$-6,816,114
Operating Gains Losses	-	$722	-
Investing Activities
Investing Cash Flow	$0	$3,924,664	$-3,784,187
Cash Flow From Continuing Investing Activities	$0	$3,924,664	$-3,784,187
Capital Expenditure	-	$-1,846	-
Financing Activities
Repurchase Of Capital Stock	$0	$-50,000	$0
Financing Cash Flow	$1,500,000	$-50,000	$0
Cash Flow From Continuing Financing Activities	$1,500,000	$-50,000	$0
Net Common Stock Issuance	$0	$-50,000	$0
Other
Issuance Of Debt	$1,500,000	$0	-
End Cash Position	$236,400	$681,098	$2,529,756
Beginning Cash Position	$681,098	$2,529,756	$13,130,057
Changes In Cash	$-444,698	$-1,848,658	$-10,600,301
Common Stock Payments	$0	$-50,000	$0
Net Issuance Payments Of Debt	$1,500,000	$0	-
Net Short Term Debt Issuance	$1,500,000	$0	-
Short Term Debt Issuance	$1,500,000	$0	-
Net Investment Purchase And Sale	$0	$3,926,510	$-3,784,187
Sale Of Investment	$0	$8,260,198	$7,345,000
Purchase Of Investment	$0	$-4,333,688	$-11,129,187
Net PPE Purchase And Sale	$0	$-1,846	$0
Purchase Of PPE	$0	$-1,846	$0
Change In Working Capital	$429,474	$-1,190,381	$813,146
Change In Other Current Liabilities	$-112,521	$-106,022	$-99,801
Change In Payables And Accrued Expense	$517,686	$-1,081,565	$907,680
Change In Accrued Expense	$303,112	$-748,966	$853,309
Change In Interest Payable	$100,881	$5,000	$9,007
Change In Payable	$214,574	$-332,599	$54,371
Change In Account Payable	$214,574	$-332,599	$54,371
Change In Prepaid Assets	$24,309	$-2,794	$5,667
Stock Based Compensation	$1,353,489	$269,669	$608,239
Amortization Of Securities	$0	$-66,521	$-76,524
Depreciation Amortization Depletion	$119,976	$118,594	$120,985
Depreciation And Amortization	$119,976	$118,594	$120,985
Depreciation	$119,976	$118,594	$120,985
Net Income From Continuing Operations	$-3,847,637	$-4,855,405	$-8,281,960
Interest Paid Supplemental Data	-	$0	$993
Change In Other Current Assets	-	$0	$-400
Gain Loss On Investment Securities	-	$722	-

Fetched: 2026-07-15